BioCentury
ARTICLE | Clinical News

Phase III frown lines data boost Revance shares

December 5, 2017 8:28 PM UTC

Revance Therapeutics Inc. (NASDAQ:RVNC) rose $8.75 (34%) to $34.75 Tuesday after reporting that a single injection of DaxibotulinumtoxinA for Injection (RT002) met the primary and all secondary endpoints in the Phase III SAKURA 1 and SAKURA 2 trials to treat moderate to severe glabellar lines, or frown lines between the eyebrows. Revance hopes to submit a BLA to FDA for the candidate in 1H19.

Revance said that if approved, RT002 would be the first neuromodulator with a long-acting duration of six months. Marketed neuromodulators have shown a duration of activity of three to four months in treating glabellar lines, according to Revance. The injectable botulinum toxin type A uses Revance's TransMTS technology...

BCIQ Company Profiles

Revance Therapeutics Inc.